Brown & Brown (BRO) Q4 2025 Earnings Transcript

Brown & Brown reported Q4 revenue of $1.607 billion, up 35.7%, with adjusted EPS rising 8.1% to $0.93 and adjusted EBITDAC margin flat at 32.9%. Full-year revenue grew 23%, cash flow from operations increased 23.5% to $1.45 billion, and dividends rose 10%, but organic revenue declined 2.8% in Q4 and management flagged lower investment income and continued Specialty Distribution headwinds in 2026. The company also raised its long-term EBITDAC margin target to 32%-37% and guided to $30 million-$40 million of 2026 EBITDA synergies from Accession integration, partially offset by litigation risk tied to 275 employees leaving for a competitor.

Analysis

BRO’s setup is better than the headline growth prints suggest because the business is increasingly being valued on cash conversion and mix, not just organic revenue. The key second-order benefit is that higher contingent commissions and Accession synergies can offset weaker reported organic growth for several quarters, which should support multiple stability even if the market keeps obsessing over “softening” growth. The revised long-term margin range signals management has more confidence in the post-deal earnings power than the quarter alone implies.

The real near-term drag is not the legal headline by itself, but the possibility of slow-burn client leakage and retention friction across employee benefits and specialty distribution over the next 2-4 quarters. That creates a subtle risk: reported organic growth may look worse before the legal process resolves, while the company is simultaneously absorbing lower investment income from the deal-funded cash rundown. If rates stay stable and casualty remains firm, the business should re-accelerate into the back half of 2026, but the first half looks more valuation-consolidative than momentum-positive.

The market may be underestimating how much of BRO’s earnings model is insulated from a mild rate rollover because the company can still monetize underwriting profitability through contingents and cross-sell. The flip side is that this makes the stock more sensitive to a true downturn in carrier profitability than many investors realize: if loss experience normalizes faster than premium growth, contingents could disappoint and earnings quality would compress. Net: this is not a broken story, but it is one where expectations for smooth compounding need to be reset lower on revenue, not on cash generation.

Key Decisions for Investors

• Stay long BRO, but size it as a cash-flow compounder rather than a pure organic-growth story; use a 6-12 month horizon and add on any pullback tied to first-half 2026 organic noise.
• Pair trade: long BRO / short a more rate-sensitive insurance distributor with less contingent commission support for the next 2-3 quarters; BRO should show better downside resilience if commercial pricing stays orderly.
• Buy BRO Jan-2027 call spreads on weakness: the setup is for second-half 2026 re-acceleration as Accession synergies and revenue phasing turn more favorable; risk/reward improves if the market over-penalizes Q1-Q2 noise.
• Avoid chasing the stock into any legal headline-driven spike; the litigation is a months-long overhang, and the cleaner entry is after the market prices in the first evidence of retained-client stability.